Estrogen deprivation therapies, such as selective estrogen receptor modulators (SERMs), have demonstrated promise in cancer treatment by stimulating NK cell and CD8+ T cell activation, particularly in peripheral blood from triple-negative breast cancer (TNBC) patients 170. Here, ESR1 is linked to cancer.